Trial Profile
Romiplostim versus standard-of-care in patients with chronic nonsplenectomised immune thrombocytopenia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Feb 2011
Price :
$35
*
At a glance
- Drugs Romiplostim (Primary)
- Indications Thrombocytopenia
- Focus Therapeutic Use
- Sponsors Amgen
- 23 Feb 2011 New trial record